Phase Scientific International Limited

Phase Scientific International Limited develops proprietary diagnostic technology and rapid testing solutions for early disease detection, with focus on cancer and infectious diseases. The company's core innovation is PHASIFY™, a molecular detection platform that enables faster, easier identification of target biomarkers compared to conventional diagnostics. PHASIFY™ powers three product and service lines: INDICAID® at-home rapid tests for point-of-care use; INDICAID lab™ at-home laboratory testing kits; and PHASE lab, a clinical laboratory service offering cancer and infectious disease testing. Recent product launches include FebriDx®, a respiratory pathogen test awarded FDA CLIA waiver (March 2026), and urine-based HPV screening for cervical cancer detection. The company markets solutions for cancer screening, cervical health monitoring, and respiratory/infectious disease diagnostics. Manufacturing and regulatory capabilities include FDA CLIA certification and active clinical research partnerships. The company has raised $34 million Series A funding and maintains operations in Asia and North America, positioning itself as an innovator in preventive diagnostics and non-invasive biomarker detection.